AOD-9604: Targeted Fat Metabolism Research for Men & Women

Author: PepGen Lab Research Team
Published: February 19, 2026

Disclaimer: This article discusses published laboratory and clinical research. AOD-9604 is a research peptide and is not approved to diagnose, treat, cure, or prevent any disease.

Overview

Many men and women struggle with stubborn fat that resists diet and exercise—especially abdominal and visceral fat. Research into AOD-9604 explores how a specific fragment of human growth hormone (hGH) may influence fat metabolism directly, without triggering the broader systemic growth effects associated with full hGH.

AOD-9604 is a synthetic version of the fat-targeting portion of hGH (amino acids 176–191). Unlike full growth hormone, studies show it does not elevate IGF-1 levels, which makes it unique in metabolic research.

In preclinical and early human trials, AOD-9604 has been studied for its ability to:

Stimulate fat breakdown (lipolysis)

Reduce new fat formation (lipogenesis)

Support body composition changes when combined with diet and exercise

Maintain metabolic stability without altering glucose or IGF-1

What Is AOD-9604 & How Does It Work?

AOD-9604 mimics the fat-burning region of hGH rather than the full hormone.

In research models, it appears to:

Activate pathways linked to beta-3 adrenergic receptors in fat tissue

Stimulate triglyceride breakdown into glycerol and free fatty acids

Encourage fat oxidation for energy use

Avoid muscle growth stimulation or IGF-1 elevation

In simple terms:
Lab studies suggest AOD-9604 may signal fat cells to release stored fat for energy, while limiting the formation of new fat—without affecting broader growth pathways.

Core Research Findings

1. Fat Breakdown (Lipolysis)

Preclinical studies show increased breakdown of stored fat in adipose tissue. Obesity models demonstrated significant reductions in body fat mass.

2. Reduced Fat Formation (Anti-Lipogenesis)

Research suggests AOD-9604 may slow the creation of new fat cells and reduce fat storage signaling.

3. Abdominal / Visceral Focus

Some studies indicate preferential reduction of abdominal fat deposits, which are commonly associated with metabolic resistance.

4. Metabolic Stability

Unlike full hGH, AOD-9604 has not been shown to raise IGF-1 or significantly alter blood glucose in clinical studies.

Research Across Different Populations

While not approved for treatment, research has explored its potential in various groups:

             Group                                                  Common Challenge                                    Research Observation

Active men & women                                Stubborn fat despite training                   May enhance fat oxidation when paired with diet & exercise

Adults 30–50                                                Slower metabolism, visceral gain            Modest body fat reduction in trials

Menopause / Andropause                       Hormone-related fat redistribution         Targeted lipolysis observed in research

Obesity models                                          Weight loss plateaus                                     Significant fat reduction in animal studies 

Clinical Research Overview

Preclinical (Animal) Studies

Obese rodent models showed up to 50% reduction in weight gain

Increased fat oxidation observed

No major toxicity signals reported

Human Phase II Trials

Studied in 300–500 overweight/obese participants

Demonstrated strong tolerability

Showed modest weight reduction when combined with diet and exercise

Development discontinued due to limited commercial efficacy—not safety concerns

Safety Data

Across more than 900 participants:

Well tolerated

No IGF-1 elevation

No significant glucose disruption

Side effect profile similar to placebo

Safety & Research Profile

Compared to full human growth hormone, AOD-9604 has demonstrated:

IGF-1 neutrality

No stimulation of systemic growth pathways

Favorable tolerability in clinical trials

However, all applications remain investigational.

Research Use Considerations

Doses studied in research have ranged widely (0.25 mg–54 mg depending on model and delivery method).

Most human trials combined AOD-9604 with dietary modification and physical activity, highlighting that metabolic signaling works in conjunction with lifestyle variables.

High purity research material is essential to ensure accurate and reproducible experimental outcomes. 

Conclusion

AOD-9604 represents a targeted metabolic research peptide designed to mimic the fat-regulating fragment of hGH without activating IGF-1 pathways.

Preclinical and early human studies suggest it may:

Promote stored fat breakdown

Limit new fat accumulation

Support body composition research

Maintain metabolic stability

While findings are promising in controlled settings, AOD-9604 remains a research compound and is not approved for medical use.

Safe AOD-9604 Research Links (preclinical/human trials; fat metabolism focus—no therapeutic claims):

Metabolic Studies (PubMed, 2000): Lipolytic domain effects in obese models. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone 

Phase II Safety (JOFEM, 2013): Tolerability in 300 obese; no IGF-1 changes.  Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans

Safety & Metabolism Review (JOFEM, 2014): 536 subjects; oral efficacy. Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health

Phase II Obesity Benefits (BioWorld): Confirmed fat loss with lifestyle. Phase II study confirms the therapeutic benefits of AOD-9604 in obesity​

All preclinical/early trials—Research only !

Page Disclaimer:

 The information provided in this section is intended strictly for informational and research purposes only. Our articles discuss published studies, emerging scientific discussions, and general laboratory topics related to research compounds. Nothing in this section is intended to diagnose, treat, cure, or prevent any disease.